Lupin Limited announced the completion of an inspection carried out by the United States Food and Drug Administration (U.S. FDA) at its Vizag API manufacturing facility. The inspection was carried out between January 13, 2020 and January 17, 2020. The inspection for the API facility at Vizag closed with five 483 observations.